Theravance Biopharma Highlights Approval of Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US, Is Entitled To Receive 85% Economic Interest In Trelegy Ellipta Royalties